

Zydus' Neshor Pharmaceuticals gets USFDA final approval for Oseltamivir Powder for Oral Suspension

Ahmedabad, 16 September 2017

Zydus' Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA received final approval from the USFDA to market Oseltamivir Powder for Oral Suspension, 6 mg/ml which is used in the treatment and prevention of influenza.

It will be produced at the Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA. The sales of Oseltamivir Powder for Oral Suspension are estimated at \$367.92 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT July 2017, extracted September 2017.*

The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.